EXHIBIT 10.10
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.
Memorandum
Shionogi & Co., Ltd. and Peninsula Pharmaceuticals, Inc. hereby agree to attach
the Doripenem Development Plan attached hereto to the License Agreement on
S-4661 dated July 11, 2002 as Appendix IV in accordance with the Subsection
3.3(b)of the License Agreement.
Date: March 17th, 2003
Shionogi & Co., Ltd. Peninsula Pharmaceuticals, Inc.
/s/ Xxxxxx Xxxxxx Sawada /s/ Xxxx Xxxx
__________________________________ _______________________________
Xxxxxx Xxxxxx Sawada Xxxx Xxxx, M.D.
General Manager, Senior Vice President
Strategic Development Department Clinical Development
Pharmaceutical Research &
Development Division
[*]
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.
